0000899243-20-020725.txt : 20200730 0000899243-20-020725.hdr.sgml : 20200730 20200730080049 ACCESSION NUMBER: 0000899243-20-020725 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200728 FILED AS OF DATE: 20200730 DATE AS OF CHANGE: 20200730 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: GADICKE ANSBERT CENTRAL INDEX KEY: 0001134655 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39401 FILM NUMBER: 201059270 MAIL ADDRESS: STREET 1: THE JOHN HANCOCK TOWER STREET 2: 200 CLARENDON STREET, 54TH FLOOR CITY: BOSTON STATE: MA ZIP: 02116 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: UBS Oncology Impact Fund L.P. CENTRAL INDEX KEY: 0001691428 STATE OF INCORPORATION: E9 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39401 FILM NUMBER: 201059271 BUSINESS ADDRESS: STREET 1: 450 KENDALL STREET CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: 617-425-9200 MAIL ADDRESS: STREET 1: 450 KENDALL STREET CITY: CAMBRIDGE STATE: MA ZIP: 02142 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: MPM Oncology Impact Management GP LLC CENTRAL INDEX KEY: 0001721035 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39401 FILM NUMBER: 201059272 BUSINESS ADDRESS: STREET 1: 450 KENDALL STREET CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: 6174259200 MAIL ADDRESS: STREET 1: 450 KENDALL STREET CITY: CAMBRIDGE STATE: MA ZIP: 02142 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: MPM Oncology Impact Management LP CENTRAL INDEX KEY: 0001687078 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39401 FILM NUMBER: 201059273 BUSINESS ADDRESS: STREET 1: 450 KENDALL STREET CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: 6174259200 MAIL ADDRESS: STREET 1: 450 KENDALL STREET CITY: CAMBRIDGE STATE: MA ZIP: 02142 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Oncology Impact Fund (Cayman) Management L.P. CENTRAL INDEX KEY: 0001721036 STATE OF INCORPORATION: E9 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39401 FILM NUMBER: 201059274 BUSINESS ADDRESS: STREET 1: 450 KENDALL STREET CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: 6174259200 MAIL ADDRESS: STREET 1: 450 KENDALL STREET CITY: CAMBRIDGE STATE: MA ZIP: 02142 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: iTeos Therapeutics, Inc. CENTRAL INDEX KEY: 0001808865 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 139 MAIN STREET CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: 857-204-4583 MAIL ADDRESS: STREET 1: 139 MAIN STREET CITY: CAMBRIDGE STATE: MA ZIP: 02142 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-07-28 0 0001808865 iTeos Therapeutics, Inc. ITOS 0001134655 GADICKE ANSBERT C/O MPM CAPITAL 450 KENDALL STREET CAMBRIDGE MA 02142 1 0 1 0 0001691428 UBS Oncology Impact Fund L.P. C/O MPM CAPITAL 450 KENDALL STREET CAMBRIDGE MA 02142 0 0 0 1 X* 0001721035 MPM Oncology Impact Management GP LLC C/O MPM CAPITAL 450 KENDALL STREET CAMBRIDGE MA 02142 0 0 0 1 X* 0001687078 MPM Oncology Impact Management LP C/O MPM CAPITAL 450 KENDALL STREET CAMBRIDGE MA 02142 0 0 0 1 X* 0001721036 Oncology Impact Fund (Cayman) Management L.P. C/O MPM CAPITAL 450 KENDALL STREET CAMBRIDGE MA 02142 0 0 0 1 X* Common Stock 2020-07-28 4 C 0 1269230 A 1269230 I See Footnote Common Stock 2020-07-28 4 C 0 84655 A 84655 I See Footnote Common Stock 2020-07-28 4 C 0 43687 A 43687 I See Footnote Common Stock 2020-07-28 4 C 0 801619 A 801619 I See Footnote Common Stock 2020-07-28 4 C 0 42605 A 42605 I See Footnote Common Stock 2020-07-28 4 C 0 15820 A 15820 I See Footnote Common Stock 2020-07-28 4 C 0 1397574 A 1397574 I See Footnote Common Stock 2020-07-28 4 C 0 724702 A 1993932 I See Footnote Common Stock 2020-07-28 4 C 0 48336 A 132991 I See Footnote Common Stock 2020-07-28 4 C 0 24944 A 68381 I See Footnote Common Stock 2020-07-28 4 C 0 457706 A 1259325 I See Footnote Common Stock 2020-07-28 4 C 0 24326 A 66931 I See Footnote Common Stock 2020-07-28 4 C 0 9033 A 24853 I See Footnote Common Stock 2020-07-28 4 C 0 797983 A 2195557 I See Footnote Common Stock 2020-07-28 4 P 0 89955 19.00 A 2083887 I See Footnote Common Stock 2020-07-28 4 P 0 5994 19.00 A 138985 I See Footnote Common Stock 2020-07-28 4 P 0 3096 19.00 A 71727 I See Footnote Common Stock 2020-07-28 4 P 0 56814 19.00 A 1316139 I See Footnote Common Stock 2020-07-28 4 P 0 3020 19.00 A 69951 I See Footnote Common Stock 2020-07-28 4 P 0 1121 19.00 A 25974 I See Footnote Common Stock 2020-07-28 4 P 0 160000 19.00 A 2355557 I See Footnote Series B Preferred Stock 2020-07-28 4 C 0 3824591 D Common Stock 1269230 0 I See Footnote Series B Preferred Stock 2020-07-28 4 C 0 255094 D Common Stock 84655 0 I See Footnote Series B Preferred Stock 2020-07-28 4 C 0 131645 D Common Stock 43687 0 I See Footnote Series B Preferred Stock 2020-07-28 4 C 0 2415530 D Common Stock 801619 0 I See Footnote Series B Preferred Stock 2020-07-28 4 C 0 128384 D Common Stock 42605 0 I See Footnote Series B Preferred Stock 2020-07-28 4 C 0 47674 D Common Stock 15820 0 I See Footnote Series B Preferred Stock 2020-07-28 4 C 0 4211330 D Common Stock 1397574 0 I See Footnote Series B-2 Preferred Stock 2020-07-28 4 C 0 2361805 D Common Stock 724702 0 I See Footnote Series B-2 Preferred Stock 2020-07-28 4 C 0 157529 D Common Stock 48336 0 I See Footnote Series B-2 Preferred Stock 2020-07-28 4 C 0 81295 D Common Stock 24944 0 I See Footnote Series B-2 Preferred Stock 2020-07-28 4 C 0 1491666 D Common Stock 457706 0 I See Footnote Series B-2 Preferred Stock 2020-07-28 4 C 0 79281 D Common Stock 24326 0 I See Footnote Series B-2 Preferred Stock 2020-07-28 4 C 0 29440 D Common Stock 9033 0 I See Footnote Series B-2 Preferred Stock 2020-07-28 4 C 0 2600628 D Common Stock 797983 0 I See Footnote Each share of Series B Convertible Preferred stock is convertible at any time, at the Reporting Person's election, into Common Stock, based on the then-applicable conversion rate and has no expiration date. The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2014 LP will convert automatically into 1,269,230 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2014 (B) LP will convert automatically into 84,655 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Asset Management Investors BV 2014 LLC will convert automatically into 43,687 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2018 LP will convert automatically into 801,619 shares of Common Stock upon the closing of the Issuer's initial public offering. (Continued From footnote 2) The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2018 (B) LP will convert automatically into 42,605 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Asset Management Investors BV 2018 LLC will convert automatically into 15,820 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by UBS Oncology Impact Fund LP will convert automatically into 1,397,574 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2014 LP will convert automatically into 724,702 shares of Common Stock upon the closing of the Issuer's initial public offering. (Continued From footnote 3) The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2014 (B) LP will convert automatically into 48,336 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Asset Management Investors BV 2014 LLC will convert automatically into 24,944 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2018 LP will convert automatically into 457,706 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2018 (B) LP will convert automatically into 24,326 shares of Common Stock upon the closing of the Issuer's initial public offering. (Continued From footnote 4) The shares of Series B-2 Convertible Preferred stock held by MPM Asset Management Investors BV 2018 LLC will convert automatically into 9,033 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by UBS Oncology Impact Fund LP ("UBS Oncology") will convert automatically into 797,983 shares of Common Stock upon the closing of the Issuer's initial public offering. These amounts reflect a 1-for-3.3115 reverse stock split which became effective on July 20, 2020. These securities are owned directly by MPM Bio Ventures 2014 LP. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein These securities are owned directly by MPM Bio Ventures 2014 (B) LP. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein These securities are owned directly by MPM Asset Management Investors BV 2014 LLC. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein These securities are owned directly by MPM Bio Ventures 2018 LP. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein. These securities are owned directly by MPM Bio Ventures 2018 (B) LP. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein. These securities are owned directly by MPM Asset Management Investors BV 2018 LLC. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein. These securities are owned directly by UBS Oncology. MPM Oncology Impact Management GP LLC ("Oncology GP LLC") is the General Partner of MPM Oncology Impact Management LP, the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is the managing director of Oncology GP LLC. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein. Each share of Series B-2 Convertible Preferred stock is convertible at any time, at the Reporting Person's election, into Common Stock, based on the then-applicable conversion rate and has no expiration date. On July 28, 2020, MPM Bio Ventures 2014 LP purchased 89,955 shares of Common Stock of the Issuer at a price of $19.00 per share pursuant to an underwritten public offering. On July 28, 2020, MPM Bio Ventures 2014 (B) LP purchased 5,994 shares of Common Stock of the Issuer at a price of $19.00 per share pursuant to an underwritten public offering. On July 28, 2020, MPM Asset Management Investors BV 2014 LLC purchased 3,096 shares of Common Stock of the Issuer at a price of $19.00 per share pursuant to an underwritten public offering. On July 28, 2020, MPM Bio Ventures 2018 LP purchased 56,814 shares of Common Stock of the Issuer at a price of $19.00 per share pursuant to an underwritten public offering. On July 28, 2020, MPM Bio Ventures 2018 (B) LP purchased 3,020 shares of Common Stock of the Issuer at a price of $19.00 per share pursuant to an underwritten public offering. On July 28, 2020, MPM Asset Management Investors BV 2018 LLC purchased 1,121 shares of Common Stock of the Issuer at a price of $19.00 per share pursuant to an underwritten public offering. On July 28, 2020, UBS Oncology purchased 160,000 shares of Common Stock of the Issuer at a price of $19.00 per share pursuant to an underwritten public offering. * affiliated funds of Reporting Person /s/ Ansbert Gadicke, Ansbert Gadicke 2020-07-30 /s/ Ansbert Gadicke, managing director of MPM Oncology Impact Management GP LLC, the general partner of MPM Oncology Impact Management LP, the general partner of Oncology Impact Fund (Cayman) Management L.P., the GP of UBS Oncology Impact Fund L.P. 2020-07-30 /s/ Ansbert Gadicke, managing director of MPM Oncology Impact Management GP LLC 2020-07-30 /s/ Ansbert Gadicke, managing director of MPM Oncology Impact Management GP LLC, the general partner of MPM Oncology Impact Management LP 2020-07-30 /s/ Ansbert Gadicke, managing director of MPM Oncology Impact Management GP LLC, the general partner of MPM Oncology Impact Management LP, the general partner of Oncology Impact Fund (Cayman) Management L.P. 2020-07-30